Oruka Therapeutics (ORKA) Capital Expenditures (2010 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Capital Expenditures of $73000.0 for Q1 2026, up 461.54% year-over-year from $13000.0 in Q1 2025, and up 15.87% quarter-over-quarter from $63000.0 in Q4 2025.
Powered by 
Analysis
Oruka Therapeutics (ORKA) Capital Expenditures (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Capital Expenditures history runs 14 years deep, the most recent figure standing at $73000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 461.54% year-over-year to $73000.0; the TTM figure through Mar 2026 stood at $269000.0 (up 2345.45% YoY), while the FY2025 annual figure was $209000.0, up 386.05% from the prior year.
- Capital Expenditures for Q1 2026 stood at $73000.0, up from $63000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $99000.0 in Q3 2025, with the low at -$2000.0 in Q4 2022.
- The 3-year median for Capital Expenditures is $34000.0 (2025), against an average of $40285.7.
- The sharpest annual moves came in 2022 and 2026: Capital Expenditures sank 66.67% in 2022, then jumped 461.54% in 2026.
- Oruka Therapeutics' Capital Expenditures stood at -$2000.0 in 2022, then soared by 3250.0% to $63000.0 in 2025, then increased by 15.87% to $73000.0 in 2026.
- Business Quant data shows ORKA's Capital Expenditures at $73000.0 in Q1 2026, $63000.0 in Q4 2025, and $99000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Oruka Therapeutics | 5.85 Bn | 4.12 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 73,000.00 |
| Dec 31, 2025 | 63,000.00 |
| Sep 30, 2025 | 86,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | 18,000.00 |
| Sep 30, 2024 | 128,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | 7,000.00 |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | 16,000.00 |
| Mar 31, 2021 | 6,000.00 |
| Dec 31, 2020 | 7,000.00 |
| Sep 30, 2020 | 6,000.00 |
| Jun 30, 2020 | 3,000.00 |
| Mar 31, 2020 | 3,000.00 |
| Dec 31, 2019 | 2,000.00 |
| Sep 30, 2018 | 3,000.00 |
| Mar 31, 2018 | 1,000.00 |
| Dec 31, 2017 | 1,000.00 |
| Dec 31, 2016 | 129,000.00 |